40
Participants
Start Date
November 15, 2017
Primary Completion Date
April 16, 2018
Study Completion Date
April 16, 2018
MED2005
(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
Nitrostat 0.6Mg Sublingual Tablet
Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
Nitro Pohl
to be dosed intravenously in Part 2 of the study
Simbec Research Limited, Merthyr Tydfil
Lead Sponsor
Futura Medical Developments Ltd.
INDUSTRY